Abstract
Background: Glioblastoma multiforme (GBM) is the most frequent brain tumor. Despite recent advances in treatment approaches the prognosis remains poor, with a median overall survival of 14.6 months. Immunotherapy is the subject of ongoing research and its benefit is becoming evident in other malignancies. Immune check-points such as cytotoxic T lymphocyte associated antigen 4 (CTLA-4), programmed cell death receptor (PD-1) and indoleamine 2,3-dioxygenase (IDO) reduce immune response.
Objective: To clarify the role of immune check point inhibitors in GBM management. Methods: Preclinical and clinical trials of immune check-point inhibitors in GBM were obtained by searching for English peer-reviewed articles on PubMed databases, trials registered on clincaltrials. gov and abstracts recently presented at international congresses. Results: Immune check point inhibitors may be of critical importance for the design of future immunotherapy approaches in GBM management. Conclusion: Immune check-point inhibitors should be considered a promising treatment option in GBM.Keywords: Immunotherapy, glioblastoma multiforme, check-point, radiotherapy, PD-1, CTLA-4, ipilimumab, immune system.
Current Cancer Drug Targets
Title:New Approaches in Glioblastoma Multiforme: The Potential Role of Immune- check Point Inhibitors
Volume: 17 Issue: 3
Author(s): Francesca De Felice, Daniela Musio, Raffaele Cassese, Giovanni Luca Gravina and Vincenzo Tombolini
Affiliation:
Keywords: Immunotherapy, glioblastoma multiforme, check-point, radiotherapy, PD-1, CTLA-4, ipilimumab, immune system.
Abstract: Background: Glioblastoma multiforme (GBM) is the most frequent brain tumor. Despite recent advances in treatment approaches the prognosis remains poor, with a median overall survival of 14.6 months. Immunotherapy is the subject of ongoing research and its benefit is becoming evident in other malignancies. Immune check-points such as cytotoxic T lymphocyte associated antigen 4 (CTLA-4), programmed cell death receptor (PD-1) and indoleamine 2,3-dioxygenase (IDO) reduce immune response.
Objective: To clarify the role of immune check point inhibitors in GBM management. Methods: Preclinical and clinical trials of immune check-point inhibitors in GBM were obtained by searching for English peer-reviewed articles on PubMed databases, trials registered on clincaltrials. gov and abstracts recently presented at international congresses. Results: Immune check point inhibitors may be of critical importance for the design of future immunotherapy approaches in GBM management. Conclusion: Immune check-point inhibitors should be considered a promising treatment option in GBM.Export Options
About this article
Cite this article as:
Felice De Francesca, Musio Daniela, Cassese Raffaele, Gravina Luca Giovanni and Tombolini Vincenzo, New Approaches in Glioblastoma Multiforme: The Potential Role of Immune- check Point Inhibitors, Current Cancer Drug Targets 2017; 17 (3) . https://dx.doi.org/10.2174/1568009616666160813183738
DOI https://dx.doi.org/10.2174/1568009616666160813183738 |
Print ISSN 1568-0096 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5576 |
Call for Papers in Thematic Issues
Advances in Cancer Biomarkers and Potential Drug Targets: From Diagnosis to Therapy
Cancer biomarkers play a crucial role in the diagnosis, prognosis, and treatment of cancer. They provide valuable information for cancer detection, risk assessment, treatment selection, and monitoring response to therapy. With advancements in molecular biology and high-throughput technologies, there has been an increasing interest in identifying and characterizing cancer biomarkers ...read more
Novel Therapeutic Approaches to Target Drug Resistant Tumors
With the development of disciplines such as chemical biology and molecular biology, the genes or proteins closely related to tumor occurrence and development have gradually become clear. Targeted therapies targeting these genes or proteins provide more effective methods for tumor treatment. Tumor targeted drugs generally only act on specific targets ...read more
ROLE OF IMMUNE AND GENOTOXIC RESPONSE BIOMARKERS IN TUMOR MICROENVIRONMENT IN CANCER DIAGNOSIS AND TREATMENT
Biological biomarkers have been used in medical research as an indicator of a normal or abnormal process inside the body, or of a disease. Nowadays, various researchers are in process to explore and investigate the biological markers for the early assessment of cancer. DNA Damage response (DDR) pathways and immune ...read more
Targeting the battlefield between host and tumor: basic research and clinical practice on reshaping tumor immune microenvironment
Immune system protects host against malignant tumors through effector cells and molecules. Cancer development and its response to therapy are regulated by inflammation, which either promotes or suppresses cancer progression. Chronic inflammation facilitates cancer progression and treatment resistance, whereas induction of acute inflammatory reactions often lead to anti-cancer immune responses. ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Targeting Ras-RAF-ERK and its Interactive Pathways as a Novel Therapy for Malignant Gliomas
Current Cancer Drug Targets The Targets of Curcumin
Current Drug Targets Targeting Proteasomes with Naturally Occurring Compounds in Cancer Treatment
Current Cancer Drug Targets PET in Anti-Cancer Drug Development and Therapy
Recent Patents on Anti-Cancer Drug Discovery Targeting Matrix Metalloproteinases in Inflammatory Conditions
Current Drug Targets Targeting the Tumor Proteasome as a Mechanism to Control the Synthesis and Bioactivity of Matrix Macromolecules
Current Molecular Medicine Aldehyde Dehydrogenase as a Marker for Stem Cells
Current Stem Cell Research & Therapy In Vitro Evidence for Competitive TSPO Binding of the Imaging Biomarker Candidates Vinpocetine and Two Iodinated DAA1106 Analogues in Post Mortem Autoradiography Experiments on Whole Hemisphere Human Brain Slices
Current Radiopharmaceuticals Mesenchymal Stem Cells and Their Cell Surface Receptors
Current Rheumatology Reviews Farnesyltransferase Inhibitors: A Comprehensive Review Based on Quantitative Structural Analysis
Current Medicinal Chemistry p53: A Guide to Apoptosis
Current Cancer Drug Targets A Multi-targeted Natural Flavonoid Myricetin Suppresses Lamellipodia and Focal Adhesions Formation and Impedes Glioblastoma Cell Invasiveness and Abnormal Motility
CNS & Neurological Disorders - Drug Targets Role of Angiogenesis Inhibitors in Colorectal Cancer: Sensitive and Insensitive Tumors
Current Cancer Drug Targets Actively Targeted Nanoparticles for Drug Delivery to Tumor
Current Drug Metabolism Resveratrol and Lifespan in Model Organisms
Current Medicinal Chemistry Mechanisms of Resistance to Photodynamic Therapy
Current Medicinal Chemistry Recent Patents on Genetic Programming
Recent Patents on Computer Science Histological and Direct Evidence for the Role of Complement in the Neuroinflammation of AD
Current Alzheimer Research IAPs, their Antagonists and their Role in Neurological Disease and Cancer
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents Adaptor Protein 3BP2 and Cherubism
Current Medicinal Chemistry